This conversation begins with a broader look at the strategies behind developing combination agents and the role these combination therapies will play in what Mazen Noureddin describes as the coming “combo-combo” world.
The group agrees that 2 or 3 agents are the most they can see in a combination therapy at this time. They all agree that some patients will require combination therapies while others will succeed with monotherapies. This will be linked with disease severity. Naim also shares another long term study he is working on.
